Why the study?
Conventional monitoring modalities often fail to adequately capture atrial fibrillation recurrence, while advances in wearables and AI have positioned consumer smartwatches as potential tools for continuous rhythm surveillance.
Does smartwatch-based AF monitoring improve the detection of AF recurrence and characterization of AF burden compared to traditional monitoring modalities in patients with atrial fibrillation?
Does smartwatch-based AF monitoring improve the detection of AF recurrence and characterization of AF burden compared to traditional monitoring modalities in patients with atrial fibrillation?
Smartwatch-based AF monitoring holds promise to complement established diagnostic tools for more proactive, individualized AF management, though robust clinical validation and regulatory frameworks are still needed.
May complement traditional AF monitoring; leaves open need for prospective validation before practice change.
Atrial fibrillation (AF) is the most common sustained arrhythmia and a growing global health burden, yet conventional monitoring with Holter devices, event recorders and implantable loop recorders often fails to adequately capture recurrence. Rapid advances in digital health, wearable biosensors and artificial intelligence (AI) have transformed consumer smartwatches and wearables into potential clinical tools capable of continuous, real-world rhythm surveillance. This narrative review synthesizes contemporary evidence on smartwatch-based AF monitoring, spanning core technologies-photoplethysmography, single-lead electrocardiography and AI fusion algorithms-and validation studies across post-ablation follow-up. Compared with traditional modalities, smartwatch-based AF monitoring demonstrates improved detection of AF recurrence, enhanced characterization of AF burden, symptom-rhythm correlation, and greater patient engagement. At the same time, key limitations are critically examined, including motion artifacts, false-positive alerts, short recording windows, adherence dependence, digital literacy and access gaps, as well as unresolved issues around regulation, interoperability and data privacy. By integrating engineering advances with guideline-directed care pathways, smartwatch-based AF monitoring holds promise to complement, rather than immediately replace, established diagnostic tools and to enable more proactive, individualized AF management. Future work must focus on robust clinical validation, equitable implementation and clear regulatory frameworks to safely scale these technologies.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: